# Masatoshi Eto

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/masatoshi-eto/

## Facts

| Field | Value |
| --- | --- |
| Citations | 11,103 |
| Field | Renal cell carcinoma treatment |
| h-index | 50 |
| i10-index | 238 |
| Last Known Institution | Kyushu University |
| OpenAlex ID | https://openalex.org/A5000508958 |
| ORCID iD | 0000-0002-3312-9930 |
| Works | 742 |

## Researcher papers

- [Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma](https://scholariq.org/papers/lenvatinib-plus-pembrolizumab-or-everolimus-for-advanced-renal-cell-carcinoma/)
- [Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/pembrolizumab-versus-placebo-as-post-nephrectomy-adjuvant-therapy-for-clear-cell/)
- [Macrophage infiltration and its prognostic relevance in clear cell renal cell carcinoma](https://scholariq.org/papers/macrophage-infiltration-and-its-prognostic-relevance-in-clear-cell-renal-cell/)
- [Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial](https://scholariq.org/papers/axitinib-versus-placebo-as-an-adjuvant-treatment-of-renal-cell-carcinoma-results/)
- [Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study](https://scholariq.org/papers/lenvatinib-plus-pembrolizumab-versus-sunitinib-in-first-line-treatment-of/)
- [Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study](https://scholariq.org/papers/lenvatinib-plus-pembrolizumab-versus-sunitinib-as-first-line-treatment-of/)
- [Randomised phase III study of neoadjuvant chemotherapy with methotrexate, doxorubicin, vinblastine and cisplatin followed by radical cystectomy compared with radical cystectomy alone for muscle-invasive bladder cancer: Japan Clinical Oncology Group Study JCOG0209](https://scholariq.org/papers/randomised-phase-iii-study-of-neoadjuvant-chemotherapy-with-methotrexate/)
- [Castration resistance of prostate cancer cells caused by castration-induced oxidative stress through Twist1 and androgen receptor overexpression](https://scholariq.org/papers/castration-resistance-of-prostate-cancer-cells-caused-by-castration-induced/)
- [Highly immunogenic cancer cells require activation of the WNT pathway for immunological escape](https://scholariq.org/papers/highly-immunogenic-cancer-cells-require-activation-of-the-wnt-pathway-for/)
- [Clinical Practice Guidelines for Bladder Cancer 2019 update by the Japanese Urological Association: Summary of the revision](https://scholariq.org/papers/clinical-practice-guidelines-for-bladder-cancer-2019-update-by-the-japanese/)
- [Assessment of surgical skills by using surgical navigation in robot-assisted partial nephrectomy](https://scholariq.org/papers/assessment-of-surgical-skills-by-using-surgical-navigation-in-robot-assisted/)

## Researcher topics

- [Renal cell carcinoma treatment](https://scholariq.org/topics/renal-cell-carcinoma-treatment/)
- [Prostate Cancer Treatment and Research](https://scholariq.org/topics/prostate-cancer-treatment-and-research/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Bladder and Urothelial Cancer Treatments](https://scholariq.org/topics/bladder-and-urothelial-cancer-treatments/)
- [Prostate Cancer Diagnosis and Treatment](https://scholariq.org/topics/prostate-cancer-diagnosis-and-treatment/)

## Researcher university

- [Kyushu University](https://scholariq.org/institutions/kyushu-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.